takeda
Turning The Tide On Dengue: How Climate Change, Urbanization And Innovation Shape Control Strategies
Tackling dengue requires a holistic approach—integrating immunization through vaccines and community-driven initiatives can nip dengue in the bud.
Takeda Completes Acquisition Of Shire
The acquisition of Shire allows Takeda to expand its R&D efforts in four therapeutic areas: oncology, gastroenterology, neuroscience and rare diseases.
Takeda Commits US$100 Million To Regenerative Medicine Startup Ambys
Takeda has committed US$100 million to support the development of therapies for chronic liver diseases at Ambys.
Takeda Establishes Center Of Excellence In Singapore
Takeda Pharmaceuticals has entered into a multi-year partnership with the Singapore Economic Development Board to support the recruitment and training of local talent for vaccine process optimization.
Takeda’s Zika Vaccine Moves Into The Fast Lane
TAK-426, Takeda’s Zika vaccine currently in phase 1 trials, has received US Food and Drug Administration’s Fast Track designation.
Promising Clinical Results For Takeda’s Dengue Vaccine
Takeda’s dengue vaccine candidate TAK-003 has been shown to provide protection against all four serotypes of the virus for at least 18 months.
Takeda Donates US$1 Million To Asian University For Women
The donation will be used to establish the Takeda Chair in Public Health, which aims to propel research and create opportunities for collaboration with scholars in public health.
Takeda And Schrödinger Team Up For Drug Discovery
Takeda Pharmaceutical Company and Schrödinger Incorporated have established a multi-target partnership for drug discovery.
T-CiRA & RIKEN To Tackle Rare Disease With iPS Cells
CiRA of Kyoto University, Takeda and RIKEN are collaborating to discover a drug for a rare genetic disorder called NGLY1 deficiency.
Promising Results For Takeda’s Dengue Vaccine
Takeda's dengue vaccine has proven to be safe and able to produce an antibody response against all four serotypes of dengue in an interim analysis of their ongoing Phase 2 trial.
